We advised the sales agent on the SEC-registered offering of ADSs

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Inventiva S.A. of its American depositary shares (ADSs). Inventiva’s ADSs are listed on the Nasdaq Global Market under the symbol “IVA” and its ordinary shares are listed on Euronext Paris under the symbol “IVA.”

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Jeannette Safi and Courtney Y. Sohn. Partner Jacques Naquet-Radiguet and associates Stéphane Daniel and Johann Jabes provided advice on matters of French law. Partner David R. Bauer and associate S. Dream Montgomery provided intellectual property advice. The tax team included counsel Alon Gurfinkel. Members of the Davis Polk team are based in the New York, Paris and London offices.

Copy link to share post